Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

settlement

- PMLiVE

Teva submits FDA application for paediatric Tourette syndrome therapy

Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years

- PMLiVE

FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients

One in ten children and adolescents in the US are affected by the neurological condition

- PMLiVE

Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn

About ten million people worldwide are affected by inflammatory bowel disease

- PMLiVE

NFID and CDC urge US adults to get vaccinated against flu and COVID-19

A survey revealed that more than 40% of US adults may not get vaccinated this autumn and winter

- PMLiVE

CDC awards over $23m to Johns Hopkins Center for Health Security project

The five-year grant will be used to help launch a new epidemic preparedness project

- PMLiVE

FDA approves second over-the-counter naloxone nasal spray for opioid overdose

Over 105,000 fatal opioid overdoses were reported in the US between 2022 and 2023

- PMLiVE

FDA panel backs over-the-counter use of Emergent BioSolutions’ Narcan

The nasal spray works by blocking the effects of an opioid overdose if administered in time

- PMLiVE

Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

Nearly 500,000 died from an opioid overdose between 1999 and 2019

- PMLiVE

Pfizer announces positive phase 3 results of RSV vaccine candidate in older adults

It is estimated that RSV infections in older adults account for 177,000 hospitalisations and 14,000 deaths each year in the US alone

- PMLiVE

AbbVie’s Allergan reaches proposed $2.37bn agreement to settle US opioid lawsuits

Together with Teva Pharmaceutical’s proposed $4.25bn deal, the total settlement deal could be worth $6.6bn

- PMLiVE

Teva reaches proposed $4.25bn agreement to settle US opioid lawsuits

The figure includes the supply of up to $1.2bn of Teva’s Narcan, a life-saving medication which can reverse an overdose from opioids

- PMLiVE

COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals

The report concluded that resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links